CARGO Therapeutics, Inc. (NASDAQ: CRGX) (“CARGO” or the “Company”) is a clinical-stage oncology-focused cell therapy biotechnology company. The Company’s lead program, CRG-022, is an autologous (derived from a patient’s cells) CD22 CAR T-cell product candidate that is being studied in a Phase 1 clinical trial in patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy. Beyond the lead program, the Company is leveraging its proprietary cell engineering platform technologies to develop a pipeline of programs that incorporate multiple transgene therapeutic “cargo” designed to enhance CAR T-cell persistence and trafficking to tumor lesions, as well as to help safeguard against tumor resistance and T-cell exhaustion.